Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.

Authors

Jordyn Silverstein, Oladunni Alomaja, Deandra Chatram, Maryam Hajiabbasi, Eliya Shachar, Chi-Hong Tseng, Shivani Thaker, Aditya Bardia, Beth Karlan, Andrea Wahner Hendrickson, Gottfried E Konecny

Published in

Gynecologic oncology reports. Volume 66. Pages 102183. Epub Aug 12, 2026.

Abstract

ObjectiveTrastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, received FDA approval on April 5, 2024 for HER2-expressing solid tumors based on the phase II DESTINY-PanTumor02 trial (n = 40 per tumor type). Despite rapid clinical adoption, real-world evidence in gynecologic cancers remains limited. This study aims to address this gap.MethodsThis single-center retrospective cohort study included patients with ovarian cancer (OC) or endometrial cancer (EC) who received T-DXd between September 2022 and January 2026. Primary outcomes were real-world progression free survival (rwPFS) and real-world response rate (rwRR). Secondary outcomes included real-world disease control rate (rwDCR), safety, and time on treatment (TOT). Exploratory analysis aimed to evaluate predictors of progression or death on T-DXd using multivariate cox regression.ResultsAs of February 2026, 40 patients (20 OC, 20 EC) received T-DXd, with a median follow-up of 23 months. All 40 were analyzed for PFS; 37 were response evaluable. HER2 IHC expression was 12.5% 1+, 62.5% 2+, and 20% 3+. Median rwPFS was 6.2 months (95% CI, 3.3-8.6), with a rwRR of 45.9% and rwDCR of 67.6%. rwRR increased significantly with HER2 expression (1+ 16.7%, 2+ 39.1%, 3+ 86%, p = 0.03). In multivariate analysis, PARP inhibitor exposure was associated with significantly shorter PFS (HR 4.36, p = 0.04). Four patients (10%) developed pneumonitis: three (7.5%) grade 1/2, and one (2.5%) grade 3.
T-DXd demonstrated promising real-world clinical outcomes in OC and EC that mirror DESTINY-PanTumor02. Responses were observed across HER2 IHC expression levels (1+ to 3+), with highest rwRR among HER2 3+. Prior PARP inhibitor exposure was associated with significantly shorter PFS, warranting further exploration.

PMID:
42621866
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.